Skip to main content

Advertisement

Log in

Management of CKD-MBD in non-dialysis patients under regular nephrology care: a prospective multicenter study

  • Original Article
  • Published:
Journal of Nephrology Aims and scope Submit manuscript

An Erratum to this article was published on 09 June 2015

Abstract

Background

Knowledge about mineral bone disorder (MBD) management in non-dialysis chronic kidney disease (ND-CKD) patients is scarce, although essential to identifying areas for therapeutic improvement.

Methods

We prospectively evaluated current management of CKD-MBD in two visits, performed 6 months apart, in 727 prevalent ND-CKD stage 3b–5 patients from 19 nephrology clinics. Therapeutic inertia was defined as lack of treatment despite hyperphosphatemia and/or hypocalcemia, and/or hyperparathyroidism. The primary endpoint was the prevalence of achieved target for CKD-MBD parameters and related treatments (phosphate binders, vitamin D and calcium supplements). The secondary endpoint was the assessment of prevalence and clinical correlates of therapeutic inertia.

Results

Over 65 % of patients did not reach parathormone (PTH) targets, while 15 and 19 % did not reach phosphate and calcium targets, respectively. The proportion of untreated patients decreased from stage 3b to 5 (at baseline, from 60 to 16 %, respectively). From baseline to the 6-month visit, the achievement of targets remained stable. Low protein diet was prescribed in 26 % of patients, phosphate binders in 17.3 % (calcium-based binders 15.5 %, aluminium binders 1.8 %), and vitamin D in 50.5 %. The overall prevalence of therapeutic inertia at the 6-month visit was 34.0 % (for hyperphosphatemia, 54.3 %). Compared to CKD stage 3, the likelihood of therapeutic inertia was 40 and 68 % lower at stage 4 and 5, respectively.

Conclusions

PTH, calcium and phosphate targets were not reached in a significant proportion of patients. One-third of patients with at least one MBD parameter not-at-target remained untreated. Therapeutic inertia regarding CKD-MBD treatment may be a major barrier to optimizing the prevention and cure of CKD-MBD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Yeo FE, Villines TC, Bucci JR, Taylor AJ, Abbott KC (2004) Cardiovascular risk at stage 4 and 5 nephropathy. Adv Chronic Kidney Dis 11:116–133

    Article  PubMed  Google Scholar 

  2. Foley RN, Parfrey PS, Sarnak MJ (1998) Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 9(Suppl 12):S16–S23

    PubMed  CAS  Google Scholar 

  3. Vanholder R, Massy Z, Argiles A, Spasovski G, Verbeke F, Lameire N (2005) European Uremic Toxin Work Group. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 20:1048–1056

    Article  PubMed  CAS  Google Scholar 

  4. Minutolo R, Locatelli F, Gallieni M, Bonofiglio R, Fuiano G, Oldrizzi L, Conte G, De Nicola L, Mangione F, Esposito P, Dal Canton A (2013) REport of COmorbidities in non-Dialysis Renal Disease Population in Italy (RECORD-IT) Study Group. Anemia management in non-dialysis chronic kidney disease (CKD) patients: a multicenter prospective study in renal clinics. Nephrol Dial Transplant 28:3035–3045

    Article  PubMed  CAS  Google Scholar 

  5. Bhuriya R, Li S, Chen SC, McCullough PA, Bakris GL (2009) Plasma parathyroid hormone level and prevalent cardiovascular disease in CKD stages 3 and 4: an analysis from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 53(Suppl 4):S3–S10

    Article  PubMed  CAS  Google Scholar 

  6. Palmer SC, Hayen A, Macaskill P, Pellegrini F, Craig JC, Elder GJ, Strippoli GF (2011) Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA 305:1119–1127

    Article  PubMed  CAS  Google Scholar 

  7. Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, Sherrard DJ, Andress DL (2005) Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 16:520–528

    Article  PubMed  CAS  Google Scholar 

  8. Schwarz S, Trivedi BK, Kalantar-Zadeh K, Kovesdy CP (2006) Association of disorders in mineral metabolism with progression of chronic kidney disease. Clin J Am Soc Nephrol 1:825–831

    Article  PubMed  CAS  Google Scholar 

  9. Voormolen N, Noordzij M, Grootendorst DC, Beetz I, Sijpkens YW, van Manen JG, Boeschoten EW, Huisman RM, Krediet RT, Dekker FW (2007) PREPARE study group. High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients. Nephrol Dial Transpl 22:2909–2916

    Article  CAS  Google Scholar 

  10. Eddington H, Hoefield R, Sinha S, Chrysochou C, Lane B, Foley RN, Hegarty J, New J, O’Donoghue DJ, Middleton RJ, Kalra PA (2010) Serum phosphate and mortality in patients with chronic kidney disease. Clin J Am Soc Nephrol 5:2251–2257

    Article  PubMed  PubMed Central  Google Scholar 

  11. Bellasi A, Mandreoli M, Baldrati L, Corradini M, Di Nicolò P, Malmusi G, Santoro A (2011) Chronic kidney disease progression and outcome according to serum phosphorus in mild-to-moderate kidney dysfunction. Clin J Am Soc Nephrol 6:883–891

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  12. De Nicola L, Chiodini P, Zoccali C, Borrelli S, Cianciaruso B, Di Iorio B, Santoro D, Giancaspro V, Abaterusso C, Gallo C, Conte G, Minutolo R, SIN-TABLE CKD Study Group (2011) Prognosis of CKD patients receiving outpatient nephrology care in Italy. Clin J Am Soc Nephrol 6:2421–2428

    Article  PubMed  PubMed Central  Google Scholar 

  13. Zoccali C, Ruggenenti P, Perna A, Leonardis D, Tripepi R, Tripepi G, Mallamaci F, Remuzzi G; REIN Study Group (2011) Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition. J Am Soc Nephrol 22:1923–1930

    Article  Google Scholar 

  14. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, Andress DL (2007) Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 71:31–38

    Article  PubMed  CAS  Google Scholar 

  15. Craver L, Marco MP, Martínez I, Rue M, Borràs M, Martín ML, Sarró F, Valdivielso JM, Fernández E (2007) Mineral metabolism parameters throughout chronic kidney disease stages 1–5—achievement of K/DOQI target ranges. Nephrol Dial Transplant 22:1171–1176

    Article  PubMed  CAS  Google Scholar 

  16. Moranne O, Froissart M, Rossert J, Gauci C, Boffa JJ, Haymann JP, M’rad MB, Jacquot C, Houillier P, Stengel B, Fouqueray B, NephroTest Study Group (2009) Timing of onset of CKD-related metabolic complications. J Am Soc Nephrol 20:164–171

    Article  PubMed  PubMed Central  Google Scholar 

  17. Desai N, Madhavankutty Saraswathy V, Hunter K, McFadden C (2013) Prevalence of true therapeutic inertia in blood pressure control in an academic chronic kidney disease clinic. J Clin Hypertens (Greenwich) 15:375–379

    Article  Google Scholar 

  18. Minutolo R, Sasso FC, Chiodini P, Cianciaruso B, Carbonara O, Zamboli P, Tirino G, Pota A, Torella R, Conte G, De Nicola L (2006) Management of cardiovascular risk factors in advanced type 2 diabetic nephropathy: a comparative analysis in nephrology, diabetology and primary care settings. J Hypertens 24:1655–1661

    Article  PubMed  CAS  Google Scholar 

  19. Martínez-Castelao A, Górriz JL, Portolés JM, De Alvaro F, Cases A, Luño J, Navarro-González JF, Montes R, De la Cruz-Troca JJ, Natarajan A, Batlle D (2011) Baseline characteristics of patients with chronic kidney disease stage 3 and stage 4 in Spain: the MERENA observational cohort study. BMC Nephrol 12:53

    Article  PubMed  PubMed Central  Google Scholar 

  20. Nordio M, Postorino M, Casino F, Mancini E, Salomone M, Conte F (2005) Standardization criteria to ensure the uniformity of data collection by the Italian Registry of Dialysis and Transplantation. Giorn It Nefrol 22:152–158

    CAS  Google Scholar 

  21. National Kidney Foundation (2003) K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42(4 Suppl 3):S1–S201

    Google Scholar 

  22. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group (2009) KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 113:S1–S130

    Google Scholar 

  23. De Nicola L, Gabbai FB, Agarwal R, Chiodini P, Borrelli S, Bellizzi V, Nappi F, Conte G, Minutolo R (2013) Prevalence and prognostic role of resistant hypertension in chronic kidney disease patients. J Am Coll Cardiol 61:2461–2467

    Article  PubMed  Google Scholar 

  24. Vassalotti JA, Uribarri J, Chen SC, Li S, Wang C, Collins AJ, Calvo MS, Whaley-Connell AT, McCullough PA, Norris KC (2008) Kidney Early Evaluation Program Investigators. Trends in mineral metabolism: Kidney Early Evaluation Program (KEEP) and the National Health and Nutrition Examination Survey (NHANES) 1999–2004. Am J Kidney Dis 51:S56–S68

    Article  PubMed  Google Scholar 

  25. Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K (2008) Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med 168:397–403

    Article  PubMed  CAS  Google Scholar 

  26. Kovesdy CP, Kalantar-Zadeh K (2008) Vitamin D receptor activation and survival in chronic kidney disease. Kidney Int 73:1355–1363

    Article  PubMed  CAS  Google Scholar 

  27. Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K (2008) Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease. Kidney Int 73:1296–1302

    Article  PubMed  CAS  Google Scholar 

  28. Cannata-Andía JB, Rodriguez García M, Gómez Alonso C (2013) Osteoporosis and adynamic bone in chronic kidney disease. J Nephrol 26:73–80

    Article  PubMed  Google Scholar 

  29. La’ulu SL, Roberts WL (2010) Performance characteristics of six intact parathyroid hormone assays. Am J Clin Pathol 134:930–938

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This study was designed by the Treatment of CKD Study Group of Italian Society of Nephrology. This study was funded by an unrestricted grant provided by Roche to the Italian Society of Nephrology.

Conflict of interest

The authors declare that they have no conflict of interest related to this research.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

The study protocol was approved by the ethical committee of each participating center and patients were enrolled after signing informed consent.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Maurizio Gallieni.

Additional information

For the REport of COmorbidities in non-dialysis Renal Disease population in ITaly (RECORD-IT) Study Group.

The complete list of authors is reported in the “Appendix”.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 397 kb)

Appendix: Complete list of investigators

Appendix: Complete list of investigators

A. Dal Canton, P. Esposito (University of Pavia. Pavia), M. Formica, M. Tamagnone (Savigliano and Ceva Hospitals, Cuneo), G. Segoloni, L. Colla (University of Torino, Torino), M. Gallieni (S. Carlo Borromeo Hospital, Milano), F. Locatelli, M.M. Corti (A. Manzoni Hospital, Lecco), R. Tarchini, C.D. Marseglia (C. Poma Hospital, Mantova), G. Meneghel, A. Nardelotto (Dolo General Hospital, Dolo), L. Oldrizzi, V. Cosentini (Fracastoro Hospital, San Bonifacio), M. Cossu (SS Annunziata Hospital, Sassari), S. Di Giulio, M. Beraldi (S. Camillo Forlanini Hospital, Roma), M. Malaguti (S. Paolo Hospital, Civitavecchia), F. Pizzarelli, P. Dattolo (S. M. Annunziata, Firenze), G. Quintaliani, Claudia Savignani (S. Maria della Misericordia Hospital, Perugia), B. Cianciaruso, A. Pisani (University “Federico II”, Naples), G. Conte, N. De Luca, R. Minutolo, M. Pacilio (Second University of Naples, Naples), R. Bonofiglio (Ospedale dell’Annunziata, Cosenza), G. Fuiano, P. Cianfrone (University of Catanzaro, Catanzaro), G. Grandaliano (University of Foggia, Foggia), G. Bellinghieri, D. Santoro (University of Messina, Messina).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gallieni, M., De Luca, N., Santoro, D. et al. Management of CKD-MBD in non-dialysis patients under regular nephrology care: a prospective multicenter study. J Nephrol 29, 71–78 (2016). https://doi.org/10.1007/s40620-015-0202-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40620-015-0202-4

Keywords

Navigation